Literature DB >> 19559819

Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.

Noreen Hossain1, Arian Afendy, Maria Stepanova, Fatema Nader, Manirath Srishord, Nila Rafiq, Zachary Goodman, Zobair Younossi.   

Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. We investigated factors associated with advanced fibrosis in NAFLD.
METHODS: The study included 432 patients with histologically proven NAFLD (26.8% with nonalcoholic steatohepatitis [NASH] and 17.4% with moderate-to severe fibrosis). NASH was defined as steatosis, lobular inflammation, and ballooning degeneration with or without Mallory-Denk bodies and/or fibrosis. Fibrosis was classified into 2 groups: those with no or minimal fibrosis and those with moderate-to-severe fibrosis. Groups were compared using Mann-Whitney and chi-square method analyses. A model was constructed using a stepwise bidirectional method; its predictive power was measured using a 10-fold cross-validation technique.
RESULTS: Patients with NASH were more likely to be male (P < .0001); have lower hip-to-waist ratios (P = .03); were less likely to be African American (P = .06); have higher levels of alanine aminotransferase (ALT; P < .0001), aspartate aminotransferase (AST; P < .0001), and serum triglycerides (P = .0154), but lower levels of high-density lipoprotein cholesterol (P < .0001). Patients with moderate-to-severe fibrosis were older (P = .0245); more likely to be male (P = .0189), Caucasian (P = .0382), have diabetes mellitus (P = .0238), and hypertension (P = .0375); and have a lower hip-to-waist ratio (P = .0077) but higher serum AST (P < .0001) and ALT (P < .0001) levels. The multivariate analysis model to predict moderate-to-severe fibrosis included male sex, Caucasian ethnicity, diabetes mellitus, and increased AST and ALT levels (model P value < .0001).
CONCLUSIONS: In patients with NAFLD, diabetes mellitus and aminotransferase levels are independent predictors of moderate-to-severe fibrosis. They can be used to identify NAFLD patients at risk for advanced fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559819     DOI: 10.1016/j.cgh.2009.06.007

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  102 in total

1.  A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

Authors:  Zobair M Younossi; Sandra Page; Nila Rafiq; Aybike Birerdinc; Maria Stepanova; Noreen Hossain; Arian Afendy; Zahra Younoszai; Zachary Goodman; Ancha Baranova
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

2.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

Review 3.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 4.  Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.

Authors:  Johanna K DiStefano
Journal:  Cell Mol Life Sci       Date:  2020-06       Impact factor: 9.261

5.  The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.

Authors:  Amandeep Singh; Phuc Le; Rocio Lopez; Naim Alkhouri
Journal:  Hepatol Int       Date:  2018-01-09       Impact factor: 6.047

6.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

7.  A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients.

Authors:  Alex Ulitsky; Ashwin N Ananthakrishnan; Richard Komorowski; James Wallace; Sri Naveen Surapaneni; Jose Franco; Kia Saeian; Samer Gawrieh
Journal:  Obes Surg       Date:  2010-06       Impact factor: 4.129

8.  The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.

Authors:  Reona Morio; Hideyuki Hyogo; Masahiro Hatooka; Kei Morio; Hiromi Kan; Tomoki Kobayashi; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hiroshi Aikata; Hidenori Ochi; Yoneda Masayasu; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2016-06-28       Impact factor: 7.527

Review 9.  Fatty liver disease in diabetes mellitus.

Authors:  Harikrashna B Bhatt; Robert J Smith
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

10.  Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study.

Authors:  George Boon-Bee Goh; An Pan; Wan-Cheng Chow; Jian-Min Yuan; Woon-Puay Koh
Journal:  Liver Int       Date:  2016-09-16       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.